X4 Pharmaceuticals
XFOR
51 hedge funds and large institutions have $5.33M invested in X4 Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 52 closing their positions.
1,745% more call options, than puts
Call options by funds: $738K | Put options by funds: $40K
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
8.92% less ownership
Funds ownership: 57.36% → 48.44% (-8.9%)
45% less funds holding
Funds holding: 93 → 51 (-42)
60% less capital inflows, than outflows
Capital inflows: $2.37M | Capital outflows: $5.98M
81% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
+$543K |
| 2 |
Jane Street
New York
|
+$398K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$318K |
| 4 |
UBS O'Connor
Chicago,
Illinois
|
+$293K |
| 5 |
Millennium Management
New York
|
+$284K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$1.6M |
| 2 |
BlackRock
New York
|
-$826K |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$529K |
| 4 |
ACA
Acorn Capital Advisors
New York
|
-$368K |
| 5 |
State Street
Boston,
Massachusetts
|
-$353K |
XFOR Hedge Fund Activity: Q2 2025 in Review
51 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2025, worth a combined $5.33M — down 77% from $23.6M a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of XFOR and 10 opened new positions — a net loss of 42 holders — while 17 trimmed existing stakes and 16 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $543K. The largest seller was OrbiMed, exiting entirely with an estimated $1.6M sold.
- 51 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2025, down from 93 in Q1 2025.
- Funds reported $5.33M of X4 Pharmaceuticals stock for Q2 2025, down 77% quarter-over-quarter.
- 10 funds opened new X4 Pharmaceuticals positions in Q2 2025 and 52 closed out, a net change of -42 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2025 was GSA Capital Partners, an estimated $543K added.
- The largest X4 Pharmaceuticals seller in Q2 2025 was OrbiMed, an estimated $1.6M sold.
Based on aggregated 13F filings for Q2 2025.